ENHERTU® Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
Page 25 - Clinical Development Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Clinical Development Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Clinical Development Program Today - Breaking & Trending Today
Daiichi Sankyo Company, Limited: ENHERTU Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer
Daiichi Sankyo Company, Limited: ENHERTU Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca's ENHERTU (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. This press release features multimedia. View the full release here: https://www.businesswire.com/...
Source: finanznachrichten.de
ENHERTU® Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Ad
First HER2 directed medicine approved for patients with gastric cancer in a decadeTOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult pa...
Source: pharmiweb.com
New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo's Continued Commitment in Lung Cancer
New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo's Continued Commitment in Lung Cancer will be featured as late-breaker presentation Updated TROPION-PanTumor01 results of datopotamab deruxtecan in patients with advanced NSCLC to be highlighted Biomarker analysis from phase 1 trial of patritumab deruxtecan in patients with previously treated metastatic or locally advanced EGFR mutated NSCLC to be presented Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will present new research data across its DXd ADC portfolio including ENHERTU ...
Source: finanznachrichten.de
Investegate |ObsEva SA Announcements | ObsEva SA: ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program - European Medicines Agency Validates Yselty MAA for Uterine Fibroids; US NDA Planned for 1H 2021 - Phase 3 EDELWEISS 3 (Conducted in Europe and US) Study of Yselty for Treatment of Endometriosis is Progressing as Planned; Primary Endpoint Readout Expected 4Q 2021 - Phase 3 EDELWEISS 2 (Conducted in the United States) Yselty Endometriosis Study Discontinued Due to Enrollment Challenges; No Safety Concerns Identified GENEVA, Switzerland and BOSTON, MA (Jan 11, 2021) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a...
Source: investegate.co.uk